Literature DB >> 18568374

Effect of streptomycin on the active force of bioengineered heart muscle in response to controlled stretch.

R K Birla1, Y C Huang, R G Dennis.   

Abstract

In this study, we describe a bioreactor system to deliver controlled stretch protocols to bioengineered heart muscle (BEHMs) and test the system when streptomycin (an aminoglycoside antibiotic, which blocks stretch-activated channels) is either added to or excluded from the culture medium. Streptomycin is a very commonly used component of cell culture antibiotic-antimycotic media additives, so its effects on muscle development and functional response to mechanical signals in vitro is worthy of investigation. Our hypothesis is that BEHMs will not adapt to the applied mechanical stretch protocol when streptomycin is present in the culture medium, but will do so when streptomycin is excluded. Bioengineered heart muscles were formed by culturing primary neonatal cardiac myocytes in a fibrin gel using a method previously developed in our laboratory. A custom bioreactor system was designed using SolidWorks and structural components manufactured using fusion deposition modeling. We utilized a stretch protocol of 1 Hz, 10% strain for 7 d. BEHMs were stretched in the presence and absence of streptomycin. As controls, BEHMs were maintained in a cell culture incubator with and without streptomycin. The contractile properties of all BEHMs were evaluated to determine the active force. We were able to demonstrate compatibility of the bioreactor system with BEHMs and were able to stretch 58 constructs with zero incidence of failure. When the BEHMs were stretched in the absence of streptomycin, the active force increased from a mean value of 51.7 +/- 5.6 (N = 10) to 102.4 +/- 16.3 microN (N = 10), with p < 0.05. However, BEHMs that were stretched in the presence of streptomycin did not show any significant increase in active force generation. The average active force of BEHMs increased from a mean value of 57.6 +/- 10.2 (N = 10) to 91.4 +/- 19.8 microN (N = 10) when stretched in the presence of streptomycin. In this study, we demonstrate compatibility of the a bioreactor system with BEHMs, stability of the BEHMs in response to stretch protocols, and significant functional improvement in response to controlled stretch only when streptomycin is excluded from the culture medium, supporting our hypothesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568374     DOI: 10.1007/s11626-008-9114-0

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  33 in total

1.  Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization.

Authors:  R L Carrier; M Papadaki; M Rupnick; F J Schoen; N Bursac; R Langer; L E Freed; G Vunjak-Novakovic
Journal:  Biotechnol Bioeng       Date:  1999-09-05       Impact factor: 4.530

2.  Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes.

Authors:  W H Zimmermann; C Fink; D Kralisch; U Remmers; J Weil; T Eschenhagen
Journal:  Biotechnol Bioeng       Date:  2000-04-05       Impact factor: 4.530

Review 3.  The growth of tissue engineering.

Authors:  M J Lysaght; J Reyes
Journal:  Tissue Eng       Date:  2001-10

Review 4.  Tissue engineering: a 21st century solution to surgical reconstruction.

Authors:  J R Fuchs; B A Nasseri; J P Vacanti
Journal:  Ann Thorac Surg       Date:  2001-08       Impact factor: 4.330

5.  Self-organization of rat cardiac cells into contractile 3-D cardiac tissue.

Authors:  Keith Baar; Ravi Birla; Marvin O Boluyt; Gregory H Borschel; Ellen M Arruda; Robert G Dennis
Journal:  FASEB J       Date:  2004-12-01       Impact factor: 5.191

Review 6.  Intracellular signaling following myocardial stretch: an autocrine/paracrine loop.

Authors:  Horacio E Cingolani; Néstor G Pérez; Ernesto A Aiello; María C Camilión de Hurtado
Journal:  Regul Pept       Date:  2005-06-30

7.  Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system.

Authors:  T Eschenhagen; C Fink; U Remmers; H Scholz; J Wattchow; J Weil; W Zimmermann; H H Dohmen; H Schäfer; N Bishopric; T Wakatsuki; E L Elson
Journal:  FASEB J       Date:  1997-07       Impact factor: 5.191

8.  Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase.

Authors:  M O Boluyt; J S Zheng; A Younes; X Long; L O'Neill; H Silverman; E G Lakatta; M T Crow
Journal:  Circ Res       Date:  1997-08       Impact factor: 17.367

9.  Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium?

Authors:  J Leor; S Aboulafia-Etzion; A Dar; L Shapiro; I M Barbash; A Battler; Y Granot; S Cohen
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

10.  Mechanical stretch regimen enhances the formation of bioengineered autologous cardiac muscle grafts.

Authors:  Payam Akhyari; Paul W M Fedak; Richard D Weisel; Tsu-Yee Joseph Lee; Subodh Verma; Donald A G Mickle; Ren-Ke Li
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

View more
  3 in total

1.  Synchronized mechanical oscillations at the cell-matrix interface in the formation of tensile tissue.

Authors:  David F Holmes; Ching-Yan Chloé Yeung; Richa Garva; Egor Zindy; Susan H Taylor; Yinhui Lu; Simon Watson; Nicholas S Kalson; Karl E Kadler
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-20       Impact factor: 11.205

2.  Combating Adaptation to Cyclic Stretching By Prolonging Activation of Extracellular Signal-Regulated Kinase.

Authors:  Justin S Weinbaum; Jillian B Schmidt; Robert T Tranquillo
Journal:  Cell Mol Bioeng       Date:  2013-09       Impact factor: 2.321

3.  3D bioprinting and its potential impact on cardiac failure treatment: An industry perspective.

Authors:  Ravi K Birla; Stuart K Williams
Journal:  APL Bioeng       Date:  2020-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.